Our recently published work evaluating a popular liquid biopsy cobas® EGFR mutation test v2 (cobas v2) shows that its sensitivity for EGFR mutations is NSCLC stage-dependent [13]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.